Magic Mushroom

Metadata

Regulatory Status

United States

• DEA Schedule: Psilocybin and psilocin are Schedule I controlled substances under the Controlled Substances Act (1970). Possession, cultivation, and distribution are federal offenses.
• FDA status: No approved psilocybin drug product. FDA granted breakthrough therapy designation to COMPASS Pathways’ COMP360 for treatment-resistant depression (October 2018) and to Usona Institute’s psilocybin formulation for major depressive disorder (November 2019). A deuterated psilocybin analog (CYB003, Cybin Inc.) received breakthrough therapy designation for MDD in 2024.
• State/local decriminalization: Oregon legalized psilocybin-assisted therapy under Measure 109 (2020), with licensed service centers operational since 2023. Colorado decriminalized psilocybin and created a regulated access framework under Proposition 122 (2022). Several cities (Denver, Oakland, Santa Cruz, Seattle, Ann Arbor, Washington D.C.) have deprioritized enforcement of psilocybin possession laws.

European Union

• Status: Psilocybin is controlled in most EU member states. The Netherlands permits sale of psilocybin-containing truffles (Psilocybe tampanensis) but not P. cubensis fruiting bodies. Clinical trials with synthetic psilocybin are underway at multiple European sites (UK, Netherlands, Czech Republic, Germany, Ireland).
• Novel food status: Not applicable — controlled substance.
• EMA: No marketing authorization application filed as of early 2026.

United Kingdom

• Status: Psilocybin is a Class A drug under the Misuse of Drugs Act 1971. Clinical research proceeds under Home Office licensing. Imperial College London’s Centre for Psychedelic Research is a leading research site.

Australia

• Status: The Therapeutic Goods Administration (TGA) rescheduled psilocybin to Schedule 8 (controlled drug) effective July 1, 2023, specifically for treatment-resistant depression when prescribed by authorized psychiatrists. Australia became the first country to formally approve psilocybin for medical use, though access remains limited and tightly regulated.

Japan

• Status: Psilocybin and psilocin are controlled under the Narcotics and Psychotropics Control Act. No medical exemptions.

Brazil

• Status: Psilocybin mushrooms are not explicitly listed as controlled substances, creating a legal gray area. Some therapeutic use is occurring.

Conditions & Indications

Primary: Treatment-Resistant Depression and Major Depressive Disorder

• Treatment-resistant depression (TRD): COMPASS Pathways’ Phase 3 trials (COMP005, COMP006) demonstrated that two doses of 25 mg synthetic psilocybin administered three weeks apart, with psychological support, produced statistically significant reduction in MADRS scores compared to 1 mg control at 6 weeks. In COMP006, mean treatment difference was -3.8 MADRS points (p < 0.05). In COMP005, 25% of patients achieved clinically meaningful reduction at 6 weeks, with effects persisting through week 26.
• Major depressive disorder (MDD): Usona Institute’s Phase 2 trial (published in JAMA, 2023) showed a single 25 mg psilocybin dose produced rapid and sustained antidepressant effects. Johns Hopkins Phase 2 trial (2021) demonstrated that psilocybin-assisted therapy produced large, rapid, and sustained antidepressant effects, with 71% of participants showing greater than 50% reduction in depression severity at 4 weeks.

Secondary: End-of-Life Anxiety and Depression

• Cancer-related psychological distress: Two landmark randomized controlled trials at Johns Hopkins (Griffiths et al., 2016) and NYU (Ross et al., 2016) demonstrated that psilocybin produced rapid and sustained decreases in anxiety and depression in patients with life-threatening cancer diagnoses. Effects were maintained at 6-month follow-up with large effect sizes (Cohen’s d > 1.0). Approximately 80% of participants showed clinically significant decreases in depression and anxiety.

Secondary: Substance Use Disorders

• Tobacco cessation: Johns Hopkins pilot study (Johnson et al., 2014) showed 80% abstinence rate at 6 months following 2—3 psilocybin sessions combined with cognitive behavioral therapy, far exceeding rates for existing pharmacotherapies (typically 25—35%).
• Alcohol use disorder: Bogenschutz et al. (2022, JAMA Psychiatry) demonstrated that psilocybin-assisted therapy significantly reduced heavy drinking days compared to active placebo (diphenhydramine) at 8 months, with 48% of the psilocybin group fully abstinent.

Emerging/Preclinical

• Obsessive-compulsive disorder (OCD): Small pilot study (Moreno et al., 2006) demonstrated marked reductions in OCD symptoms with psilocybin. Larger trials underway.
• Anorexia nervosa: Phase 2 trials investigating psilocybin for treatment-resistant anorexia nervosa (Johns Hopkins, COMPASS Pathways).
• Cluster headache: Retrospective and case series data suggest psilocybin may abort cluster headache cycles and extend remission periods. Controlled trials pending.
• Post-traumatic stress disorder (PTSD): Early-phase trials evaluating psilocybin for PTSD, though MDMA-assisted therapy is further advanced for this indication.
• Neuroplasticity and cognitive flexibility: Preclinical evidence demonstrates that psilocybin promotes dendritic spine growth and synaptogenesis in cortical neurons, suggesting potential applications for neurological conditions.

Mechanism of Action

Primary Mechanisms

1. 5-HT2A receptor agonism: Psilocybin is a prodrug that is rapidly dephosphorylated by alkaline phosphatase in the gut and liver to psilocin (4-hydroxy-DMT), the pharmacologically active metabolite. Psilocin is a partial agonist at serotonin 5-HT2A receptors, which are densely expressed in cortical layer V pyramidal neurons. Activation of 5-HT2A receptors triggers downstream signaling via Gq/11 proteins, phospholipase C, and protein kinase C, leading to increased glutamate release in the prefrontal cortex and altered cortical network dynamics. This is considered the primary mechanism underlying both the acute psychedelic experience and the therapeutic effects.

2. Default mode network (DMN) disruption: Functional neuroimaging studies (Carhart-Harris et al., 2012, 2016) demonstrate that psilocin acutely decreases activity and functional connectivity within the default mode network, a brain network associated with self-referential processing, rumination, and the narrative sense of self. This DMN disruption correlates with subjective ego dissolution and is hypothesized to enable a “reset” of maladaptive cognitive patterns characteristic of depression and addiction.

3. Neuroplasticity promotion: Psilocybin increases brain-derived neurotrophic factor (BDNF) levels and promotes dendritic spine growth and synaptogenesis in cortical and hippocampal neurons. Studies in mice (Shao et al., 2021) demonstrated increased dendritic spine density in the medial frontal cortex lasting at least one month after a single psilocybin dose. This structural neuroplasticity may underlie the sustained therapeutic effects observed weeks to months after acute dosing.

4. Increased global brain connectivity: Psilocin produces a transient state of increased entropy and cross-network connectivity in the brain, allowing communication between brain regions that do not normally interact. This “entropic brain” state (Carhart-Harris, 2018) may facilitate cognitive and emotional flexibility, allowing patients to break free from rigid patterns of thought associated with depression, anxiety, and addiction.

Secondary Mechanisms

• 5-HT2C, 5-HT1A receptor activity: Psilocin also acts at 5-HT2C and 5-HT1A receptors, contributing to anxiolytic effects and modulation of downstream dopaminergic signaling.
• Anti-inflammatory effects: Psilocybin has been shown to reduce peripheral inflammatory markers (TNF-alpha, IL-6) in preclinical models, which may contribute to its antidepressant effects given the neuroinflammatory hypothesis of depression.
• Amygdala responsiveness modulation: Acute psilocybin reduces amygdala reactivity to negative emotional stimuli (Kraehenmann et al., 2015), with increased amygdala responsiveness to positive stimuli post-treatment, suggesting emotional processing rebalancing.
• Claustrum modulation: Psilocybin strongly suppresses neural activity in the claustrum, a thin brain structure theorized to integrate conscious experience. This suppression correlates with subjective effects and may contribute to the altered states of consciousness.

Clinical Evidence Summary

Phase 3 Trials

Phase 2 Trials

Evidence Limitations

• No FDA-approved product: Despite strong Phase 2 and Phase 3 results, no psilocybin product has received marketing authorization as of early 2026. Regulatory filing is anticipated from COMPASS Pathways.
• Synthetic psilocybin vs. whole mushroom: All major clinical trials use pharmaceutical-grade synthetic psilocybin, not whole P. cubensis mushroom. The therapeutic effects of whole mushroom preparations, which contain variable concentrations of psilocybin, psilocin, baeocystin, and other compounds, have not been rigorously evaluated in controlled trials.
• Blinding challenges: The pronounced subjective effects of psilocybin make true blinding difficult. Most trials use low-dose psilocybin (1 mg) or active placebos (niacin, diphenhydramine) to maintain some degree of blinding, but functional unblinding is a widely acknowledged limitation.
• Psychological support confound: All clinical trials combine psilocybin with structured psychological preparation, support during the session, and integration therapy. The relative contribution of the drug versus the therapeutic context is not fully disentangled.
• Long-term safety data limited: Most follow-up periods extend to 6—12 months. Data on repeated dosing over years and long-term neuropsychological effects are lacking.
• Population generalizability: Clinical trials have primarily enrolled participants without psychotic disorders, bipolar disorder, or active suicidality. Efficacy and safety in these excluded populations are unknown.

Safety Profile

General Assessment

Psilocybin has a favorable acute safety profile in controlled clinical settings. No deaths have been attributed to psilocybin toxicity in clinical trials. Physiological toxicity is very low, with an estimated lethal dose of approximately 280 mg/kg in humans (extrapolated from animal data), far exceeding any therapeutic dose. The primary risks are psychological rather than physiological: challenging experiences (“bad trips”), anxiety, paranoia, and rare but significant prolonged psychotic episodes in vulnerable individuals. The safety profile in uncontrolled settings is less favorable due to the absence of screening, preparation, and professional support.

Contraindications

• Psychotic spectrum disorders: Personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder is an absolute contraindication in all clinical trial protocols due to the risk of precipitating or exacerbating psychotic episodes.
• Concurrent serotonergic medications: SSRIs and SNRIs may attenuate psilocybin effects (probability of weakened response: 0.47 for SSRIs, 0.55 for SNRIs) and carry a theoretical risk of serotonin toxicity, though confirmed cases are rare. MAOIs are strictly contraindicated due to potentiation of psilocybin effects and elevated serotonin syndrome risk.
• Cardiovascular disease: Psilocybin causes transient mild-to-moderate increases in heart rate (mean +5—15 bpm) and blood pressure (mean +10—20 mmHg systolic). Severe cardiovascular disease is a contraindication.
• Pregnancy: No human safety data. Contraindicated due to serotonergic mechanism and unknown teratogenic potential.

Drug Interactions

• SSRIs/SNRIs: Attenuate psilocybin effects; rare reports of serotonin toxicity. Clinical trials have typically required a 2-week washout (5 weeks for fluoxetine). However, one COMPASS trial (Goodwin et al., 2023) allowed concomitant SSRI use and did not observe increased adverse events.
• MAOIs: Potentiate and prolong psilocybin effects; significantly elevated risk of serotonin syndrome. Strictly contraindicated.
• Lithium: Case reports of seizures with combined psilocybin and lithium. Contraindicated.
• Stimulants: Combined use may increase cardiovascular stress (heart rate, blood pressure).
• Cannabis: May potentiate or alter the psychedelic experience unpredictably. Not systematically studied.
• CYP2D6 inhibitors: Psilocin is partially metabolized by CYP2D6. Strong inhibitors could theoretically increase psilocin exposure, though clinical significance is uncertain.

Side Effects

• Common (>10% in trials): Headache (most common, typically transient), nausea, transient anxiety during onset, emotional distress during session, fatigue, insomnia on dosing day.
• Occasional (1—10%): Paranoia, confusion, dizziness, visual disturbances (persisting briefly post-session), elevated blood pressure, tachycardia.
• Rare (<1%): Prolonged psychotic symptoms (predominantly in individuals with predisposing factors), hallucinogen persisting perception disorder (HPPD), suicidal ideation (occurred in COMPASS Phase 2b trial at rates requiring monitoring).
• Challenging psychological experiences: Approximately 30% of participants in clinical trials report some degree of psychological difficulty during sessions, typically resolving with therapeutic support. These experiences are often retrospectively rated as meaningful and not distressing.

Toxicology

• Acute toxicity: Very low. No deaths from psilocybin toxicity have been confirmed in clinical or forensic literature. Estimated human LD50 is approximately 280 mg/kg (extrapolated), meaning a 70 kg person would need to ingest approximately 19.6 grams of pure psilocybin — roughly equivalent to 1—2 kg of dried P. cubensis mushrooms.
• Organ toxicity: No evidence of hepatotoxicity, nephrotoxicity, or cardiotoxicity at therapeutic doses.
• Dependence potential: Psilocybin has very low abuse liability. Rapid tolerance (tachyphylaxis) develops within days, making daily use impractical. No physical withdrawal syndrome. Not considered addictive by pharmacological criteria.
• Neurotoxicity: No evidence of neurotoxicity at therapeutic doses. Animal studies suggest neuroprotective rather than neurotoxic effects.

Clinical Dosage

Synthetic Psilocybin (Clinical Trial Context)

• Therapeutic dose: 25 mg fixed dose (equivalent to approximately 0.3 mg/kg for a 70 kg adult), administered orally in a single capsule with water. This is the dose used in most Phase 2 and Phase 3 depression trials.
• Moderate dose: 10 mg has shown some efficacy in the COMPASS Phase 2b trial but was less effective than 25 mg.
• Low/control dose: 1 mg is used as an active control in COMPASS trials (produces no psychedelic effects).
• Dosing schedule: One to two sessions, typically 3 weeks apart. Most protocols include 6—8 hours of preparation therapy, 6—8 hours of supported drug session, and 2—4 integration therapy sessions afterward.

Dried Whole Mushroom (Non-Clinical, Unregulated)

• Typical psychoactive dose: 1—5 grams of dried P. cubensis fruiting body (containing approximately 0.6—1.0% psilocybin by dry weight, yielding roughly 6—50 mg psilocybin). Potency varies significantly between specimens, flushes, and growing conditions.
• “Microdose” range: 0.1—0.3 grams dried mushroom (approximately 0.6—3 mg psilocybin). Sub-perceptual dosing; clinical evidence for efficacy is currently weak and inconclusive (multiple RCTs show no significant difference from placebo).

Important Dosing Considerations

• Set and setting: Clinical trial protocols emphasize the critical importance of therapeutic context: a comfortable environment, trained therapist presence, preparatory sessions, and integration. These elements are considered essential to safety and efficacy.
• Whole mushroom variability: Psilocybin content in P. cubensis varies from 0.14% to 1.86% dry weight depending on genetics, cultivation conditions, substrate, harvest timing, and storage. This variability makes precise dosing with whole mushroom material unreliable and is a key reason clinical trials use synthetic psilocybin.
• No established safe dose outside clinical supervision for psychiatric indications.

Sources

• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180
• Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489
• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648
• Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953-962
• Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992
• Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138-2143
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627
• Shao LX, Liao C, Greber I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-2544.e4
• Garcia-Romeu A, Barrett FS, Carbonaro TM, Johnson MW, Griffiths RR. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J Psychopharmacol. 2021;35(4):353-361
• Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). 2020;73(10):679-686
• Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166
• Spriggs MJ, Giribaldi B, Lyons T, et al. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol. 2023;37(1):107-116

Connections

• Neuroplasticity and cognitive enhancement: The dendritic spine growth and synaptogenesis promoted by psilocybin represent a neuroplasticity mechanism that parallels the nerve growth factor (NGF) stimulation attributed to Lion’s Mane. While psilocybin acts acutely via 5-HT2A receptor agonism and Lion’s Mane acts chronically via hericenones and erinacines stimulating NGF/BDNF, both approaches converge on structural neuroplasticity as a therapeutic endpoint. Anecdotal reports of combining sub-perceptual psilocybin doses with Lion’s Mane (“stacking”) are popular in wellness communities but lack clinical evidence.
• Serotonergic pharmacology: Psilocybin’s mechanism as a serotonin 5-HT2A agonist is pharmacologically distinct from the monoamine-modulating or GABAergic mechanisms of most other medicinal mushrooms. The specificity of its receptor binding profile — and the resulting profound alteration of consciousness — places it in a unique category among fungal bioactives.
• Adaptogenic context: While Reishi and Cordyceps are used for stress resilience through HPA axis modulation and adaptogenic mechanisms, psilocybin addresses psychological rigidity and treatment-resistant psychiatric conditions through a fundamentally different route: acute disruption of default mode network activity followed by enhanced neuroplasticity. These approaches are complementary in concept but have not been studied in combination.
• Regulatory precedent: The clinical development of psilocybin represents the most advanced regulatory pathway for any psychoactive fungal compound. Australia’s 2023 rescheduling of psilocybin for medical use and the anticipated regulatory filings in the US and EU may set precedents affecting how other bioactive fungal compounds are evaluated and regulated.